Pancreatic Cancer-Pipeline Review, H2 2016

Pancreatic Cancer-Pipeline Review, H2 2016


  • Products Id :- GMDHC8862IDB
  • |
  • Pages: 2006
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Global Markets Direct’s, ‘Pancreatic Cancer - Pipeline Review, H2 2016’, provides an overview of the Pancreatic Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pancreatic Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pancreatic Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

 

Scope

The report provides a snapshot of the global therapeutic landscape of Pancreatic Cancer

The report reviews pipeline therapeutics for Pancreatic Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Pancreatic Cancer therapeutics and enlists all their major and minor projects

The report assesses Pancreatic Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Pancreatic Cancer

 

Reasons to Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Pancreatic Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Pancreatic Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Introduction 14

Pancreatic Cancer Overview 15

Therapeutics Development 16

Pancreatic Cancer - Therapeutics under Development by Companies 18

Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes 45

Pancreatic Cancer - Pipeline Products Glance 49

Pancreatic Cancer - Products under Development by Companies 53

Pancreatic Cancer - Products under Investigation by Universities/Institutes 88

Pancreatic Cancer - Companies Involved in Therapeutics Development 93

Pancreatic Cancer - Therapeutics Assessment 397

Drug Profiles 478

Pancreatic Cancer - Dormant Projects 1889

Pancreatic Cancer - Discontinued Products 1922

Pancreatic Cancer - Product Development Milestones 1929

Appendix 1942

List of Figures

Number of Products under Development for Pancreatic Cancer, H2 2016 79

Number of Products under Development for Pancreatic Cancer - Comparative Analysis, H2 2016 80

Number of Products under Development by Companies, H2 2016 81

Number of Products under Investigation by Universities/Institutes, H2 2016 108

Comparative Analysis by Late Stage Development, H2 2016 112

Comparative Analysis by Clinical Stage Development, H2 2016 113

Comparative Analysis by Early Stage Products, H2 2016 114

Assessment by Monotherapy Products, H2 2016 460

Assessment by Combination Products, H2 2016 461

Number of Products by Top 10 Targets, H2 2016 462

Number of Products by Stage and Top 10 Targets, H2 2016 462

Number of Products by Top 10 Mechanism of Actions, H2 2016 504

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 504

Number of Products by Top 10 Routes of Administration, H2 2016 537

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 537

Number of Products by Top 10 Molecule Types, H2 2016 539

Number of Products by Stage and Top 10 Molecule Types, H2 2016 539

List of Tables

Number of Products under Development for Pancreatic Cancer, H2 2016 79

Number of Products under Development for Pancreatic Cancer - Comparative Analysis, H2 2016 80

Number of Products under Development by Companies, H2 2016 82

Number of Products under Development by Companies, H2 2016 (Contd..1) 83

Number of Products under Development by Companies, H2 2016 (Contd..2) 84

Number of Products under Development by Companies, H2 2016 (Contd..3) 85

Number of Products under Development by Companies, H2 2016 (Contd..4) 86

Number of Products under Development by Companies, H2 2016 (Contd..5) 87

Number of Products under Development by Companies, H2 2016 (Contd..6) 88

Number of Products under Development by Companies, H2 2016 (Contd..7) 89

Number of Products under Development by Companies, H2 2016 (Contd..8) 90

Number of Products under Development by Companies, H2 2016 (Contd..9) 91

Number of Products under Development by Companies, H2 2016 (Contd..10) 92

Number of Products under Development by Companies, H2 2016 (Contd..11) 93

Number of Products under Development by Companies, H2 2016 (Contd..12) 94

Number of Products under Development by Companies, H2 2016 (Contd..13) 95

Number of Products under Development by Companies, H2 2016 (Contd..14) 96

Number of Products under Development by Companies, H2 2016 (Contd..15) 97

Number of Products under Development by Companies, H2 2016 (Contd..16) 98

Number of Products under Development by Companies, H2 2016 (Contd..17) 99

Number of Products under Development by Companies, H2 2016 (Contd..18) 100

Number of Products under Development by Companies, H2 2016 (Contd..19) 101

Number of Products under Development by Companies, H2 2016 (Contd..20) 102

Number of Products under Development by Companies, H2 2016 (Contd..21) 103

Number of Products under Development by Companies, H2 2016 (Contd..22) 104

Number of Products under Development by Companies, H2 2016 (Contd..23) 105

Number of Products under Development by Companies, H2 2016 (Contd..24) 106

Number of Products under Development by Companies, H2 2016 (Contd..25) 107

Number of Products under Investigation by Universities/Institutes, H2 2016 108

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 109

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 110

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 111

Comparative Analysis by Late Stage Development, H2 2016 112

Comparative Analysis by Clinical Stage Development, H2 2016 113

Comparative Analysis by Early Stage Development, H2 2016 114

Comparative Analysis by Unknown Stage Development, H2 2016 115

Products under Development by Companies, H2 2016 116

Products under Development by Companies, H2 2016 (Contd..1) 117

Products under Development by Companies, H2 2016 (Contd..2) 118

Products under Development by Companies, H2 2016 (Contd..3) 119

Products under Development by Companies, H2 2016 (Contd..4) 120

Products under Development by Companies, H2 2016 (Contd..5) 121

Products under Development by Companies, H2 2016 (Contd..6) 122

Products under Development by Companies, H2 2016 (Contd..7) 123

Products under Development by Companies, H2 2016 (Contd..8) 124

Products under Development by Companies, H2 2016 (Contd..9) 125

Products under Development by Companies, H2 2016 (Contd..10) 126

Products under Development by Companies, H2 2016 (Contd..11) 127

Products under Development by Companies, H2 2016 (Contd..12) 128

Products under Development by Companies, H2 2016 (Contd..13) 129

Products under Development by Companies, H2 2016 (Contd..14) 130

Products under Development by Companies, H2 2016 (Contd..15) 131

Products under Development by Companies, H2 2016 (Contd..16) 132

Products under Development by Companies, H2 2016 (Contd..17) 133

Products under Development by Companies, H2 2016 (Contd..18) 134

Products under Development by Companies, H2 2016 (Contd..19) 135

Products under Development by Companies, H2 2016 (Contd..20) 136

Products under Development by Companies, H2 2016 (Contd..21) 137

Products under Development by Companies, H2 2016 (Contd..22) 138

Products under Development by Companies, H2 2016 (Contd..23) 139

Products under Development by Companies, H2 2016 (Contd..24) 140

Products under Development by Companies, H2 2016 (Contd..25) 141

Products under Development by Companies, H2 2016 (Contd..26) 142

Products under Development by Companies, H2 2016 (Contd..27) 143

Products under Development by Companies, H2 2016 (Contd..28) 144

Products under Development by Companies, H2 2016 (Contd..29) 145

Products under Development by Companies, H2 2016 (Contd..30) 146

Products under Development by Companies, H2 2016 (Contd..31) 147

Products under Development by Companies, H2 2016 (Contd..32) 148

Products under Development by Companies, H2 2016 (Contd..33) 149

Products under Development by Companies, H2 2016 (Contd..34) 150

Products under Investigation by Universities/Institutes, H2 2016 151

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 152

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 153

Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 154

Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 155

Pancreatic Cancer - Pipeline by 3M Drug Delivery Systems, H2 2016 156

Pancreatic Cancer - Pipeline by 4SC AG, H2 2016 157

Pancreatic Cancer - Pipeline by AB Science SA, H2 2016 158

Pancreatic Cancer - Pipeline by AbbVie Inc, H2 2016 159

Pancreatic Cancer - Pipeline by AbGenomics International Inc, H2 2016 160

Pancreatic Cancer - Pipeline by Ability Pharmaceuticals SL, H2 2016 161

Pancreatic Cancer - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 162

Pancreatic Cancer - Pipeline by Adamed Sp z oo, H2 2016 163

Pancreatic Cancer - Pipeline by Adamis Pharmaceuticals Corp, H2 2016 164

Pancreatic Cancer - Pipeline by Aduro BioTech Inc, H2 2016 165

Pancreatic Cancer - Pipeline by Advantagene Inc, H2 2016 166

Pancreatic Cancer - Pipeline by Advaxis Inc, H2 2016 167

Pancreatic Cancer - Pipeline by Agenus Inc, H2 2016 168

Pancreatic Cancer - Pipeline by AGV Discovery SAS, H2 2016 169

Pancreatic Cancer - Pipeline by AIMM Therapeutics BV, H2 2016 170

Pancreatic Cancer - Pipeline by Alchemia Ltd, H2 2016 171

Pancreatic Cancer - Pipeline by Alissa Pharma, H2 2016 172

Pancreatic Cancer - Pipeline by Allinky Biopharma, H2 2016 173

Pancreatic Cancer - Pipeline by Almac Discovery Ltd, H2 2016 174

Pancreatic Cancer - Pipeline by Altor BioScience Corp, H2 2016 175

Pancreatic Cancer - Pipeline by Ambrx Inc, H2 2016 176

Pancreatic Cancer - Pipeline by amcure GmbH, H2 2016 177

Pancreatic Cancer - Pipeline by American Gene Technologies International Inc, H2 2016 178

Pancreatic Cancer - Pipeline by Amgen Inc, H2 2016 179

Pancreatic Cancer - Pipeline by Anavex Life Sciences Corp, H2 2016 180

Pancreatic Cancer - Pipeline by Andarix Pharmaceuticals Inc, H2 2016 181

Pancreatic Cancer - Pipeline by ANP Technologies Inc, H2 2016 182

Pancreatic Cancer - Pipeline by AntiCancer Inc, H2 2016 183

Pancreatic Cancer - Pipeline by APEIRON Biologics AG, H2 2016 184

Pancreatic Cancer - Pipeline by Aphios Corp, H2 2016 185

Pancreatic Cancer - Pipeline by APIM Therapeutics AS, H2 2016 186

Pancreatic Cancer - Pipeline by Apogenix GmbH, H2 2016 187

Pancreatic Cancer - Pipeline by Aposense Ltd, H2 2016 188

Pancreatic Cancer - Pipeline by ARMO Biosciences Inc, H2 2016 189

Pancreatic Cancer - Pipeline by ArQule Inc, H2 2016 190

Pancreatic Cancer - Pipeline by Array BioPharma Inc, H2 2016 191

Pancreatic Cancer - Pipeline by Astellas Pharma Inc, H2 2016 192

Pancreatic Cancer - Pipeline by AstraZeneca Plc, H2 2016 193

Pancreatic Cancer - Pipeline by ATLAB Pharma SAS, H2 2016 194

Pancreatic Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 195

Pancreatic Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2016 196

Pancreatic Cancer - Pipeline by Axcentua Pharmaceuticals AB, H2 2016 197

Pancreatic Cancer - Pipeline by Azaya Therapeutics Inc, H2 2016 198

Pancreatic Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2016 199

Pancreatic Cancer - Pipeline by Bavarian Nordic A/S, H2 2016 200

Pancreatic Cancer - Pipeline by Bayer AG, H2 2016 201

Pancreatic Cancer - Pipeline by BeiGene Ltd, H2 2016 202

Pancreatic Cancer - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 203

Pancreatic Cancer - Pipeline by Berg LLC, H2 2016 204

Pancreatic Cancer - Pipeline by BerGenBio AS, H2 2016 205

Pancreatic Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2016 206

Pancreatic Cancer - Pipeline by Bexion Pharmaceuticals LLC, H2 2016 207

Pancreatic Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2016 208

Pancreatic Cancer - Pipeline by Bio-Path Holdings Inc, H2 2016 209

Pancreatic Cancer - Pipeline by BioLineRx Ltd, H2 2016 210

Pancreatic Cancer - Pipeline by Biomar Microbial Technologies, H2 2016 211

Pancreatic Cancer - Pipeline by Biomunex Pharmaceuticals, H2 2016 212

Pancreatic Cancer - Pipeline by Bioncotech Therapeutics SL, H2 2016 213

Pancreatic Cancer - Pipeline by Bionomics Ltd, H2 2016 214

Pancreatic Cancer - Pipeline by BioNTech AG, H2 2016 215

Pancreatic Cancer - Pipeline by BiOrion Technologies BV, H2 2016 216

Pancreatic Cancer - Pipeline by Biotest AG, H2 2016 217

Pancreatic Cancer - Pipeline by Biouniversa srl, H2 2016 218

Pancreatic Cancer - Pipeline by BLR Bio LLC, H2 2016 219

Pancreatic Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 220

Pancreatic Cancer - Pipeline by Boston Biomedical Inc, H2 2016 221

Pancreatic Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 222

Pancreatic Cancer - Pipeline by Cadila Pharmaceuticals Ltd, H2 2016 223

Pancreatic Cancer - Pipeline by Calithera Biosciences Inc, H2 2016 224

Pancreatic Cancer - Pipeline by Cantargia AB, H2 2016 225

Pancreatic Cancer - Pipeline by Cascadian Therapeutics Inc, H2 2016 226

Pancreatic Cancer - Pipeline by Cavion LLC, H2 2016 227

Pancreatic Cancer - Pipeline by Celgene Corp, H2 2016 228

Pancreatic Cancer - Pipeline by Cellceutix Corp, H2 2016 229

Pancreatic Cancer - Pipeline by Cellular Biomedicine Group Inc, H2 2016 230

Pancreatic Cancer - Pipeline by Celprogen Inc, H2 2016 231

Pancreatic Cancer - Pipeline by Celyad SA, H2 2016 232

Pancreatic Cancer - Pipeline by Centrose LLC, H2 2016 233

Pancreatic Cancer - Pipeline by Ceronco Biosciences, H2 2016 234

Pancreatic Cancer - Pipeline by ChemoCentryx Inc, H2 2016 235

Pancreatic Cancer - Pipeline by Chiome Bioscience Inc, H2 2016 236

Pancreatic Cancer - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016 237

Pancreatic Cancer - Pipeline by Clovis Oncology Inc, H2 2016 238

Pancreatic Cancer - Pipeline by COARE Biotechnology Inc, H2 2016 239

Pancreatic Cancer - Pipeline by Concordia International Corp, H2 2016 240

Pancreatic Cancer - Pipeline by Confluence Life Sciences Inc, H2 2016 241

Pancreatic Cancer - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016 242

Pancreatic Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2016 243

Pancreatic Cancer - Pipeline by CrystalGenomics Inc, H2 2016 244

Pancreatic Cancer - Pipeline by CTI BioPharma Corp, H2 2016 245

Pancreatic Cancer - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 246

Pancreatic Cancer - Pipeline by CytomX Therapeutics Inc, H2 2016 247

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

3M Drug Delivery Systems, 4SC AG, AB Science SA, AbbVie Inc, AbGenomics International Inc, Ability Pharmaceuticals SL, Acetylon Pharmaceuticals Inc, Adamed Sp z oo, Adamis Pharmaceuticals Corp, Aduro BioTech Inc, Advantagene Inc, Advaxis Inc, Agenus Inc, AGV Discovery SAS, AIMM Therapeutics BV, Alchemia Ltd, Alissa Pharma, Allinky Biopharma, Almac Discovery Ltd, Altor BioScience Corp, Ambrx Inc, amcure GmbH, American Gene Technologies International Inc, Amgen Inc, Anavex Life Sciences Corp, Andarix Pharmaceuticals Inc, ANP Technologies Inc, AntiCancer Inc, APEIRON Biologics AG, Aphios Corp, APIM Therapeutics AS, Apogenix GmbH, Aposense Ltd, ARMO Biosciences Inc, ArQule Inc, Array BioPharma Inc, Astellas Pharma Inc, AstraZeneca Plc, ATLAB Pharma SAS, Aurigene Discovery Technologies Ltd, AVEO Pharmaceuticals Inc, Axcentua Pharmaceuticals AB, Azaya Therapeutics Inc, Basilea Pharmaceutica Ltd, Bavarian Nordic A/S, Bayer AG, BeiGene Ltd, Bellicum Pharmaceuticals Inc, Berg LLC, BerGenBio AS, Betta Pharmaceuticals Co Ltd, Bexion Pharmaceuticals LLC, BeyondSpring Pharmaceuticals Inc, Bio-Path Holdings Inc, BioLineRx Ltd, Biomar Microbial Technologies, Biomunex Pharmaceuticals, Bioncotech Therapeutics SL, Bionomics Ltd, BioNTech AG, BiOrion Technologies BV, Biotest AG, Biouniversa srl, BLR Bio LLC, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Company, Cadila Pharmaceuticals Ltd, Calithera Biosciences Inc, Cantargia AB, Cascadian Therapeutics Inc, Cavion LLC, Celgene Corp, Cellceutix Corp, Cellular Biomedicine Group Inc, Celprogen Inc, Celyad SA, Centrose LLC, Ceronco Biosciences, ChemoCentryx Inc, Chiome Bioscience Inc, Chugai Pharmaceutical Co Ltd, Clovis Oncology Inc, COARE Biotechnology Inc, Concordia International Corp, Confluence Life Sciences Inc, Cornerstone Pharmaceuticals Inc, Critical Outcome Technologies Inc, CrystalGenomics Inc, CTI BioPharma Corp, Cyclacel Pharmaceuticals Inc, CytomX Therapeutics Inc, CytRx Corp, CyTuVax BV, Daewoong Pharmaceutical Co Ltd, Daiichi Sankyo Company Ltd, DEKK-TEC Inc, Diffusion Pharmaceuticals Inc, Eisai Co Ltd, Eleison Pharmaceuticals LLC, Eli Lilly and Company, Endor Nanotechnologies SL, Ensemble Therapeutics Corp, Ensol Biosciences Inc, Erytech Pharma SA, Esperance Pharmaceuticals Inc, Etubics Corp, Exelixis Inc, F. Hoffmann-La Roche Ltd, FibroGen Inc, Five Prime Therapeutics Inc, Fountain Biopharma Inc, Fujifilm Corp, Fusion Antibodies Ltd, Galena Biopharma Inc, GamaMabs Pharma SA, Ganymed Pharmaceuticals AG, Geistlich Pharma AG, Genelux Corp, Genentech Inc, Genisphere Inc, Genmab A/S, Gilead Sciences Inc, GlaxoSmithKline Plc, Globeimmune Inc, GlycoMimetics Inc, Golden Biotechnology Corp, GW Pharmaceuticals Plc, Halozyme Therapeutics Inc, HEC Pharm Co Ltd, Helix BioPharma Corp, Horizon Pharma Plc, iCeutica Inc, Igenica Biotherapeutics Inc, Ignyta Inc, Immodulon Therapeutics Ltd, Immune Pharmaceuticals Inc, Immune System Key Ltd, Immune Therapeutics Inc, Immunomedics Inc, Immunotope Inc, Immunovo BV, Immupharma Plc, Incuron LLC, Incyte Corp, Inflection Biosciences Ltd, Innopharmax Inc, Inovio Pharmaceuticals Inc, InteRNA Technologies BV, Intica Biomedical Inc, Inventiva, InvivoGen Therapeutics, Io Therapeutics Inc, ISU ABXIS Co Ltd, Jasco Pharmaceuticals LLC, Jiangsu Hengrui Medicine Co Ltd, Johnson & Johnson, Juno Therapeutics Inc, Kadmon Corp LLC, Kancera AB, Karcinolys SAS, Karyopharm Therapeutics Inc, Keystone Nano Inc, Komipharm International Co Ltd, Kura Oncology Inc, Kyowa Hakko Kirin Co Ltd, Lead Discovery Center GmbH, Lion Biotechnologies Inc, Lymphocyte Activation Technologies SA, MabVax Therapeutics Holdings Inc, MacroGenics Inc, Mateon Therapeutics Inc, MaxiVAX SA, Meabco A/S, Mebiopharm Co Ltd, MediaPharma srl, Medicenna Therapeutics Inc, MedImmune LLC, Medisyn Technologies Inc, Medivation Inc, Merck & Co Inc, Merck KGaA, Merrimack Pharmaceuticals Inc, Merus NV, Moleculin Biotech Inc, MolMed SpA, Monopar Therapeutics LLC, Morphotek Inc, Multimmune GmbH, NanoCarrier Co Ltd, NantKwest Inc, Nascent Biotech Inc, Natco Pharma Ltd, NatureWise Biotech & Medicals Corp, Nerviano Medical Sciences Srl, NewLink Genetics Corp, NormOxys Inc, Northwest Biotherapeutics Inc, Novartis AG, Noxxon Pharma AG, NuCana BioMed Ltd, Omeros Corp, Omnitura Therapeutics Inc, Oncodesign SA, Oncology Research International Ltd, Oncolytics Biotech Inc, Oncomatryx Biopharma SL, OncoMed Pharmaceuticals Inc, OncoTherapy Science Inc, Oncovir Inc, Ono Pharmaceutical Co Ltd, Onxeo SA, Opsona Therapeutics Ltd, Optimum Therapeutics LLC, Orega Biotech SAS, Oribase Pharma, Oryx GmbH & Co KG, Oscotec Inc, Patrys Ltd, Pfizer Inc, Pharma Two B Ltd, PharmAbcine Inc, Pharmacyclics Inc, PharmaCyte Biotech Inc, Pharmedartis GmbH, Phoenix Biotechnology Inc, Pique Therapeutics, Plexxikon Inc, Polaris Pharmaceuticals Inc, Precision Biologics Inc, Prima BioMed Ltd, ProNAi Therapeutics Inc, Propanc Health Group Corp, Provectus Biopharmaceuticals Inc, Quest PharmaTech Inc, Quimatryx SL, RedHill Biopharma Ltd, Redx Pharma Plc, RESprotect GmbH, Rexahn Pharmaceuticals Inc, Rhizen Pharmaceuticals SA, Rigontec GmbH, Samumed LLC, Sanofi, Sapience Therapeutics Inc, Sareum Holdings Plc, SATT North SAS, Savoy Pharmaceuticals Inc, SignPath Pharma Inc, Silence Therapeutics Plc, Sillajen Biotherapeutics, Soluventis GmbH, Soricimed Biopharma Inc, Spotlight Innovation Inc

select a license

Single User License
USD 2500 INR 167325
Site License
USD 5000 INR 334650
Corporate User License
USD 7500 INR 501975

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com